Zacks Investment Research on MSN4d
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...
Eczema: What Does It Look Like & How Can I Treat It?
Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results ...
Fierce Biotech4d
Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
HealthDay13h
Roflumilast Cream 0.05 Percent Safe, Effective in Young Children With Eczema
Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...
EurekAlert!1d
Topical steroid withdrawal diagnostic criteria defined by NIH researchers
Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid ...
Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout
Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...
Medpage Today on MSN1d
Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 Inhibitor
ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...
Topical steroid withdrawal diagnostic criteria defined by researchers
Researchers at the National Institutes of Health (NIH) have determined that dermatitis resulting from topical steroid ...